Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-ZN-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	ZINC,SERUM		
Clinical Information:			

Serum Zinc	15	umol/L	(10-25)

Tests Completed:CA19-9, IRON STUDIES, SHBG, PROGESTERONE, E2, LH, FSH, FBC
Tests Completed:ACTIVE VITAMIN B12, SE E/LFT, SE ZINC, SE VIT D, SE HOMOCYSTEINE
Tests Completed:SE CEA, ESR, SE COPPER
Tests Pending :LEUKAEMIA MARKER STUDIES

iherb. online. ✱
Thorne Zinc Picolinate.
25/30??

Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-FHM-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	FERTILITY HORMONE MASTER		
Clinical Information:			

Luteinizing Hormone	9	IU/L	
Follicle Stimulating Hormone	5	IU/L	
Oestradiol	310	pmol/L	
Progesterone	26	nmol/L	
Sex Hormone Binding Globulin	78	nmol/L	(18-114)

Ranges:	Follicular Phase	Midcycle Peak	Luteal Phase	Post-Menopausal
LH	2 - 12	10 - 130	1 - 17	15 - 60
FSH	1 - 10	3 - 33	1 - 9	20 - 140
Oestradiol	70 - 530	230 - 1310	200 - 790	< 120
Progesterone	< 5	rising	20 - 110	< 3

Pattern suggests normal Luteal phase with ovulation likely to have occurred.

Tests Completed:IRON STUDIES, SHBG, PROGESTERONE, E2, LH, FSH, FBC, SE E/LFT, SE VIT D
Tests Completed:SE HOMOCYSTEINE, SE CEA, ESR
Tests Pending :CA19-9, LEUKAEMIA MARKER STUDIES, ACTIVE VITAMIN B12, SE ZINC
Tests Pending :SE COPPER

Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-CMM-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	MASTER LYMPHOMA/LEUKAEMIA		
Clinical Information:			

CELL SURFACE MARKER ANALYSIS
Specimen Submitted : Peripheral blood
Population Reported: Standard Lymphoid Phenotype Reported.

T CELL LINEAGE		B CELL LINEAGE	
CD 7	84 %	CD19	12 %
CD 2	87 %	CD20	12 %
CD 5	82 %	SmIg	12 %
CD 3	81 %	kappa	7 %
CD 4	59 %	lambda	5 %
CD 8	18 %		
CD56	5 %		
CD16	6 %		
CD4:8	3.2		

Total Lymphocyte Count		1.9	x10 ^9 /L	(1.1-4.0)
Subsets:				
CD19+	Total B Cells	0.22	x10 ^9 /L	(0.06-0.60)
CD3+	Mature T Cells	1.51	x10 ^9 /L	(0.80-2.40)
CD4+	T Cell Subset	1.10	x10 ^9 /L	(0.50-1.60)
CD8+	T Cell Subset	0.34	x10 ^9 /L	(0.20-1.00)
CD56+	NK Cells	0.09	x10 ^9 /L	(0.07-0.60)
CD16+	NK Cells	0.11	x10 ^9 /L	

Comment:
B cell and T cell subset numbers are within normal limits.

The majority of lymphoid cells are T cells. The B cells present are polyclonal. There is no evidence of a B cell lymphoproliferative disorder.

Dr P. Davidson [Haematologist]

C11-365; BE03515

Tests Completed:CA19-9, IRON STUDIES, SHBG, PROGESTERONE, E2, LH, FSH
Tests Completed:LEUKAEMIA MARKER STUDIES, FBC, ACTIVE VITAMIN B12, SE E/LFT, SE ZINC
Tests Completed:SE VIT D, SE HOMOCYSTEINE, SE CEA, ESR, SE COPPER
Tests Pending :

Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-HOM-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	HOMOCYSTEINE,SERUM		
Clinical Information:			

CUMULATIVE SERUM HOMOCYSTEINE

Date	08/11/21
Time	06:55
Lab No	67970519
Homocysteine	11.3 umol/L (0.0-15.0)

67970519 High normal value.
With this level, the heterozygous state for defects of transsulphuration (homocysteinaemia) is unlikely. However the risk of coronary artery disease may be mildly elevated over the baseline. This is independent of other risk factors.

Homocysteine Related Risk

Plasma level (umol/L)	Risk Average
Below 9.0	No increase
9.0 - 14.9	x 2
15.0 - 19.9	x 3
20.0 or greater	x 4.5

Risks approximated from New Eng J Med 1997 (337:230-236)

Tests Completed:IRON STUDIES, FBC, SE E/LFT, SE VIT D, SE HOMOCYSTEINE, SE CEA, ESR
Tests Pending :CA19-9, SHBG, PROGESTERONE, E2, LH, FSH, LEUKAEMIA MARKER STUDIES
Tests Pending :ACTIVE VITAMIN B12, SE ZINC, SE COPPER

Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-VD-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	VITAMIN D,SERUM		
Clinical Information:			

CUMULATIVE SERUM VITAMIN D

Date	27/03/21	08/11/21	
Time	10:15	06:55	
Lab No	69916821	67970519	
Vitamin D3	70	127	nmol/L (> 49)

67970519

** Progress report.

Please note that as of 05/07/2021, QML Pathology changed to the Liaison XL analyser for Vitamin D testing at our Murrarie laboratory. Comparison studies have shown good agreement between the methods and the reference intervals have not changed. If further information is required, please contact a Chemical Pathologist on (07) 3121 4444.
Patients should contact their referring doctor in regard to this result.

Tests Completed:IRON STUDIES, FBC, SE VIT D, ESR
Tests Pending :CA19-9, SHBG, PROGESTERONE, E2, LH, FSH, LEUKAEMIA MARKER STUDIES
Tests Pending :ACTIVE VITAMIN B12, SE E/LFT, SE ZINC, SE HOMOCYSTEINE, SE CEA
Tests Pending :SE COPPER

Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-CEA-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	CARCINOEMBRYONIC ANTIGEN		
Clinical Information:			

CUMULATIVE SERUM CARCINOEMBRYONIC ANTIGEN (CEA)

Date	30/09/21	08/11/21	
Time	08:10	06:55	
Lab No	67086815	67970519	
CEA	< 0.5	< 0.5	ug/L (up to 4.6)

CEA is elevated in over 50% of gastrointestinal malignancies and in some lung and breast malignancies. It is occasionally increased (up to 10 ug/L) in some non-malignant conditions.

Tests Completed:IRON STUDIES, FBC, SE E/LFT, SE VIT D, SE HOMOCYSTEINE, SE CEA, ESR
Tests Pending :CA19-9, SHBG, PROGESTERONE, E2, LH, FSH, LEUKAEMIA MARKER STUDIES
Tests Pending :ACTIVE VITAMIN B12, SE ZINC, SE COPPER

Patient Name:	SARKIS, GEORGINA		
Patient Address:	U 2 40 CHELTENHAM DR, ROBINA 4226		
D.O.B:	24/10/1976	**Gender:**	F
Medicare No.:	25361510541	**IHI No.:**	
Lab. Reference:	21-67970519-TMM-0	**Provider:**	QML Pathology
Addressee:	DR CORNE MARE	**Referred by:**	MARE,DR. CORNE
Date Requested:	7/11/2021	**Date Performed:**	8/11/2021
Date Collected:	8/11/2021	**Complete:**	Final
Specimen:			
Subject(Test Name):	TUMOUR MARKER MASTER		
Clinical Information:			

CA 19-9 (Siemens)	26 U/mL	(< 30)

CA19-9 is associated with mucinous epithelium, and may be elevated with inflammation or Neoplasia.

Tests Completed:CA19-9, IRON STUDIES, SHBG, PROGESTERONE, E2, LH, FSH, FBC, SE E/LFT
Tests Completed:SE VIT D, SE HOMOCYSTEINE, SE CEA, ESR
Tests Pending :LEUKAEMIA MARKER STUDIES, ACTIVE VITAMIN B12, SE ZINC, SE COPPER